ArticleClinical pharmacology and therapeutics2026
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity-Matched Cohort Study.
Inbar Nardi Agmon et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.